Inotuzumab Ozogamicin and Low-Intensity Chemotherapy in Older Patients With Newly Diagnosed CD22 + Philadelphia Chromosome–Negative B-Cell Precursor Acute Lymphoblastic Leukemia
Journal of Clinical Oncology · 2024
DOI: 10.1200/jco.24.00490 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift Journal of Clinical Oncology, 2024. Verfasst von Patrice Chevallier und 40 weiteren Autor:innen. Beteiligte Einrichtung: Hematology Department, Nantes University Hospital, Nantes, France. Hauptthemen laut MEDLINE: Inotuzumab Ozogamicin, Antineoplastic Combined Chemotherapy Protocols, Sialic Acid Binding Ig-like Lectin 2, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma. Die Arbeit wurde bisher 51-mal zitiert (Crossref) und nennt 32 Literaturangaben.
Themen: Onkologische Pflege
Abstract (Originalsprache)
PURPOSE The use of inotuzumab ozogamicin (InO), a conjugated anti-CD22 monoclonal antibody, is becoming a promising frontline treatment for older patients with ALL. PATIENTS AND METHODS EWALL-INO is an open-label prospective multicenter phase II trial (ClinicalTrials.gov identifier: NCT03249870 ). Patients age 55 years and older with newly diagnosed CD22 + Philadelphia chromosome–negative (Ph–) B-cell precursor (BCP) ALL were eligible. After a prephase, a first induction consisting of vincristine, dexamethasone, and three injections of InO (0.8 mg/m 2 day 1, 0.5 mg/m 2 day 8/day 15) was followed by a second induction combining cyclophosphamide, dexamethasone, and two injections of InO (0.5 mg/m 2 day 1/day 8). Responders received up to six cycles of chemotherapy consolidation and 18-month chemotherapy maintenance. Allotransplant was allowed after three consolidations. The primary end point was 1-year overall survival (OS). RESULTS Between December 2017 and March 2022, 131 patients (median age 68 years) were included. Three patients died during induction 1 (n = 130), two from multiple organ failure and one from hemorrhage, and none during induction 2 (n = 120). After induction 2, 90% of the patients achieved complete remission (CR) or CR with incomplete platelet recovery (CRp) and 80% had measurable residual disease (MRD2)
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Hematology Department, Nantes University Hospital, Nantes, France.
- CRCI2NA, INSERM UMR 1307 & CNRS UMR 6075, IRS_UN, University of Nantes, Nantes, France.
- Hematology Department, CHU Hôpital Haut-Lévèque, Pessac, France.
- Department of Population Health Sciences, School of Life Course & Population Sciences, King's College London, London, United Kingdom.
- Institute of Hematology and Blood Transfusion and Charles University, First Faculty of Medicine, Prague, Czech Republic.
- Service d'Hématologie Biologique, Hôpital Saint-Louis-Université Paris Cité, INSERM/CNRS U944/UMR7212, Paris, France.
ORCID-Profile: Patrice Chevallier, Marc Delord, Cyril Salek, Rathana Kim, Ulla Wartiovaara-Kautto, Emmanuelle Tavernier, Hugo Bergugnat, Michael Doubek, Eolia Brissot, Sylvain Chantepie, Amine Belhabri, Claude Gardin, Sarah Bonnet, Nicolas Boissel, Herve Dombret, Emmanuelle Clappier
Zitieren
APA
Chevallier, P., Leguay, T., Delord, M., Salek, C., Kim, R., Huguet, F., Hicheri, Y., Wartiovaara-Kautto, U., Raffoux, E., Cluzeau, T., Balsat, M., Roth-Guepin, G., Tavernier, E., Lepretre, S., Bilger, K., Bergugnat, H., Berceanu, A., Alexis, M., Doubek, M., …, & European Working Group for Adult Acute Lymphoblastic Leukemia (EWALL) (2024). Inotuzumab Ozogamicin and Low-Intensity Chemotherapy in Older Patients With Newly Diagnosed CD22 + Philadelphia Chromosome–Negative B-Cell Precursor Acute Lymphoblastic Leukemia. Journal of Clinical Oncology. https://doi.org/10.1200/jco.24.00490
Vancouver
Chevallier P, Leguay T, Delord M, Salek C, Kim R, Huguet F, et al. Inotuzumab Ozogamicin and Low-Intensity Chemotherapy in Older Patients With Newly Diagnosed CD22 + Philadelphia Chromosome–Negative B-Cell Precursor Acute Lymphoblastic Leukemia. Journal of Clinical Oncology. 2024. doi:10.1200/jco.24.00490
BibTeX
@article{Chevallier2024,
author = {Chevallier, Patrice and Leguay, Thibaut and Delord, Marc and Salek, Cyril and Kim, Rathana and Huguet, Françoise and Hicheri, Yosr and Wartiovaara-Kautto, Ulla and Raffoux, Emmanuel and Cluzeau, Thomas and Balsat, Marie and Roth-Guepin, Gabrielle and Tavernier, Emmanuelle and Lepretre, Stephane and Bilger, Karin and Bergugnat, Hugo and Berceanu, Ana and Alexis, Magda and Doubek, Michael and Brissot, Eolia and Hunault-Berger, Mathilde and Lebon, Delphine and Turlure, Pascal and Chantepie, Sylvain and Belhabri, Amine and Wickenhauser, Stefan and Bastie, Jean-Noel and Cacheux, Victoria and Himberlin, Chantal and Banos, Anne and Gardin, Claude and Bonnet, Sarah and Plantier, Isabelle and Pica, Gian Matteo and Escoffre-Barbe, Martine and Boissel, Nicolas and Dombret, Herve and Clappier, Emmanuelle and Rousselot, Philippe and Group for Research on Adult Acute Lymphoblastic Leukemia (GRAALL) and the European Working Group for Adult Acute Lymphoblastic Leukemia (EWALL), Group for Research on Adult Acute Lymphoblastic Leukemia (GRAALL) and the European Working Group for Adult Acute Lymphoblastic Leukemia (EWALL) and European Working Group for Adult Acute Lymphoblastic Leukemia (EWALL), European Working Group for Adult Acute Lymphoblastic Leukemia (EWALL)},
title = {Inotuzumab Ozogamicin and Low-Intensity Chemotherapy in Older Patients With Newly Diagnosed CD22 + Philadelphia Chromosome–Negative B-Cell Precursor Acute Lymphoblastic Leukemia},
journal = {Journal of Clinical Oncology},
year = {2024},
doi = {10.1200/jco.24.00490}
}
EUVIMED